General practitioners' opinion on antihypertensive drugs deprescribing
https://doi.org/10.18705/1607-419X-2026-2570
EDN: LFPJGW
Abstract
The aim of the study was to characterize the attitude of general practitioners towards the cancellation of antihypertensive drug prescription in elderly patients and to identify the subjective main reasons for and barriers to deprescribing.
Design and methods. The cross-sectional study included 104 general practitioners who completed an anonymous face-to-face survey.
Results and discussion. 73,1 % of respondents were internists, 3,8 % specialized in geriatrics, and 23,1 % were doctors of other specialties. Most respondents (73,1 %) had more than 10 years of medical experience. 34,6 % of doctors consider clinical episodes of hypotension to be common during antihypertensive treatment in elderly and senile patients, but only 15,4 % perform survey to identify hypotension, and only 7,7 % conduct an orthostatic test. Most physicians (65,4 %) either do not conduct or rarely conduct a test for the assessment for orthostatic hypotension, and 34,6 % rarely conduct a survey to identify hypotension symptoms. The following were cited as reasons for deprescribing: a decrease in systolic blood pressure to less than 90 mmHg (34,6 %), falls (11,8 %), and less frequently (3,8 % each) — frailty, dizziness, inability to selfcare, and cognitive impairment. More than 40 % of respondents found it difficult to identify reasons for revising antihypertensive therapy. Overall, physicians' lack of awareness about the need for identification of adverse reactions and the causes of deprescribing can be considered barriers to drug deprescribing in elderly patients.
About the Authors
O. N. Antropova
Altai State Medical University
Russian Federation
Russian Federation
Oxana N. Antropova, MD, PhD, DSc, Professor, Professor of the Department of Therapy and Geriatrics
40 Lenin str., Barnaul, 656038 Phone: +7 3852 20-12-79
I. V. Osipova
Altai State Medical University
Russian Federation
Russian Federation
Irina V. Osipova, MD, PhD, DSc, Head, Department of Therapy and Geriatrics
Barnaul
A. A. Molchanova
Altai State Medical University
Anna A. Molchanova, MD, PhD, Associate Professor, Associate Professor of the Department of Therapy and Geriatrics
Barnaul
K. A. Medvedeva
Altai State Medical University
Russian Federation
Russian Federation
Kristina А. Medvedeva, Student
Barnaul
References
1. Rahimi K, Bidel Z, Nazarzadeh M, et al. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053–1064. https://doi.org/10.1016/S0140-6736(21)01921-8
2. Beckett NS, Peter R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. N Engl J Med. 2008;358:1887–1898. https://doi.org/10.1056/NEJMoa0801369
3. Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, et al. Intensive vs standard blood pressure control in adults 80 years or older: a secondary analysis of the systolic blood pressure intervention trial. J Am Geriatr Soc. 2020:68:496–504. https://doi.org/10.1111/jgs.16272
4. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older adults with hypertension. N Engl J Med. 2021;385:1268–1279. https://doi.org/10.1056/NEJMoa2111437
5. Gilyarevsky SR, Shchedrina AYu, Eruslanova KA, Kozhevnikova MV, Luzina AV, Gotina AD, et al. Evaluation of the safety of achieving recommended blood pressure targets in elderly patients: protocol of a randomized, open‑label, prospective, pragmatic study THReshOld (Treatment of Hypertension to Recommended blood pressure in Old patients with hypertension). Arterial’naya Gipertenziya = Arterial Hypertension. 2025;31(1):47–53. (In Russ.) https://doi.org/10.18705/1607-419X-2025-2401
6. United Nations. Department of Economic and Social Affairs. Population Division. World population prospects: the 2015 revision, key findings and advance tables. Working paper no. ESA/P/WP.241. New York (NY): United Nations; 2015.
7. O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onde G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625–632. https://doi.org/10.1007/s41999-023-00777-y
8. Liau SJ, Zhao M, Hamada S, Gutiérrez-Valencia M, Jadczak AD, Li Li, et al. Deprescribing opportunities for frail residents of nursing homes: a multicenter study in Australia, China, Japan, and Spain. J Am Med Dir Assoc. 2024;25(5):876–883. https://doi.org/10.1016/j.jamda.2024.01.015
9. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of hypertension endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertension. 2023;41(12):1874–2071. https://doi.org/10.1097/hjh.00000000003480
10. Gnjidic D, Johansson M, Meng DM, Farrell B, LangfordA, Reeve E. Achieving sustainable healthcare through deprescribing. Cochrane Database Syst Rev. 2022;10(10):Ed000159. https://doi.org/10.1002/14651858
11. Sheppard JP, Burt J, Mark L, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039–2051. https://doi.org/10.1001/jama.2020.4871
12. Jing B, Liu X, Graham LA, Dave CV, Li Y, Fung K, et al. Deprescribing of antihypertensive medications and cognitive function in nursing home residents. JAMA Intern Med. 2024;184(11):1347–1355. https://doi.org/10.1001/jamainternmed.2024.4851
13. Silva IM, Moreira PM , Santos AM, Castro PR, Aguiar EC, Oliveira MG, et al. Deprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial. Int J Clin Pharm. 2025;47(1):53–59. https://doi.org/10.1007/s11096-024-01805-y
14. Odden MC, Graham LA, Liu X, Dave CV, Lee SJ, Li Yo, et al. Antihypertensive deprescribing and cardiovascular events among long-term care residents. JAMA Netw Open. 2024;7(11):e2446851. https://doi.org/10.1001/jamanetworkopen.2024.46851
15. Bogaerts J, Gussekloo J, Bianca EM, Le Cessie S, Mooijaart SP, van der Mast RC, at al. Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. Age Ageing. 2024;53(7):afae133. https://doi.org/10.1093/ageing/afae133
16. Brunner L, Rodondi N, Aubert CE. Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review. BMJ Open. 2022;12(12):e061686. https://doi.org/10.1136/bmjopen-2022-061686
17. Crutzen S, Baas G, Abou J, van den Born-Bondt T, Hugtenburg JG, Bouvy ML, et al. Barriers and enablers of older patients to deprescribing of cardiometabolic medication: a focus group study. Front Pharmacol. 2020;11:1268. https://doi.org/10.3389/fphar.2020.01268
18. Abou J, Crutzen S, Tromp V, Tromp V, Heringa M, Marum RV, Elders P, et al. Barriers and enablers of healthcare providers to deprescribe cardiometabolic medication in older patients: a focus group study. Drugs Aging. 2022;39(3):209–221. https://doi.org/10.1007/s40266-021-00918-7
19. Scott IA, Le Couteur DG. Physicians need to take the lead in deprescribing. Intern Med J. 2015;45:352–356. https://doi.org/10.1111/imj.12693
20. Archer L, Koshiaris C, Lay-Flurrie S, Snell KIE, Riley RD, Stevens R, et al. Development and external validation of a risk prediction model for falls in patients with an indication for antihypertensive treatment: retrospective cohort study. Br Med J (Clinical researched). 2022;379: e070918. https://doi.org/10.1136/bmj-2022-070918
Review
For citations:
Antropova O.N., Osipova I.V., Molchanova A.A., Medvedeva K.A. General practitioners' opinion on antihypertensive drugs deprescribing. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2026;32(1):117-123. (In Russ.) https://doi.org/10.18705/1607-419X-2026-2570. EDN: LFPJGW
Views:
61
JATS XML
Email this article 